Physician profile
Abdullah Asreb
NPI 1922624428
$4,694.57
in general payments reported to CMS, 2019-2025
6 companies · $3,979 in 2025
The $3,979 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $556 · 2024: $159 · 2025: $3,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,600 · Food and Beverage: $1,578 · Education: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,599.64 |
| Food and Beverage | $1,577.76 |
| Education | $517.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,374.07 | 2023-2025 | Merlin@Home, Cardiomems, Gallant |
| Boston Scientific Corporation | $143.12 | 2024 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $97.24 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $41.06 | 2023-2024 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $23.28 | 2023 | Uptravi |
| Novo Nordisk INC | $15.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Asreb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.